A phenanthrene methanol (WR 33063) for treatment of acute malaria.
WR 33063, a phenanthrene methanol, was studied in human volunteers for tolerance and toxicity. In normal volunteers, it was possible to give 4.6 g in four divided doses without adverse effect for 10 days. At this dose level, there was neither evidence of photosensitivity nor adverse renal or cardiac effect. At a dose level of 1.6 g in four divided doses for 6 days, WR 33063 cured 18 of 23 nonimmune volunteers infected with the Smith strain of Plasmodium falciparum from Vietnam. In addition, infections due to the Marks and Braithwaite Vietnam strains were also treated because these strains represent a major therapeutic challenge to chloroquine; six of six and two of three volunteers, respectively, were cured. With the Malayan Camp strain, 1.6 g in four divided doses for 6 days cured all of five volunteers. The African Uganda I strain of chloroquine-responsive malaria was even more responsive to WR 33063; all of six men who received 1.6 g in four divided doses for 6 days were cured, and all of three men who received this same dosage for 3 days were cured. One subject infected with a Haitian strain of P. falciparum was treated and cured. Blood-induced infections with the Chesson strain of P. vivax also responded well to WR 33063 with four of five men cured. In all, 52 men received WR 33063 in tolerance trials, and 59 men with experimental malaria and one man with clinical malaria were treated with WR 33063.
D000962:Antimalarials / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006205:Haiti; D006801:Humans; D007214:Indonesia; D008288:Malaria / Q000188:drug therapy*; D000432:Methanol / Q000627:therapeutic use; D008744:Methylamines / Q000627:therapeutic use; D010616:Phenanthrenes / Q000627:therapeutic use*; D010963:Plasmodium falciparum / Q000145:classification*; D014454:Uganda; D014744:Vietnam
D000962:Antimalarials; D008744:Methylamines; D010616:Phenanthrenes; D000432:Methanol